A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

NCT05556200 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Triple-Negative Breast Cancer

Interventions

DRUG: Anti-PD-1 monoclonal antibody
DRUG: VEGFR2 Tyrosine Kinase Inhibitor

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University